Published in Nat Rev Nephrol on September 10, 2013
VA NEPHRON-D: Diabetes iN Nephropathy Study (VA NEPHRON-D) | NCT00555217
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Progression, remission, regression of chronic renal diseases. Lancet (2001) 3.17
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42
The Remission Clinic approach to halt the progression of kidney disease. J Nephrol (2011) 1.01
Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health. Clin J Am Soc Nephrol (2006) 0.90
Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment. Nat Rev Nephrol (2013) 0.85
Dual RAS blockade-unresolved controversy? Nat Rev Nephrol (2013) 0.81
Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol (2009) 0.81
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol (2003) 1.81
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int (2013) 1.81
In vivo maturation of functional renal organoids formed from embryonic cell suspensions. J Am Soc Nephrol (2012) 1.81
Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol (2005) 1.79
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol (2012) 1.75
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol (2006) 1.74
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood (2012) 1.73
Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest (2015) 1.71
ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol (2011) 1.70
Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int (2002) 1.68
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int (2013) 1.67
Eculizumab in a patient with dense-deposit disease. N Engl J Med (2012) 1.67
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Platelet dysfunction in renal failure. Semin Thromb Hemost (2004) 1.63
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol (2009) 1.59
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood (2012) 1.58
Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol (2009) 1.54
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol (2005) 1.54
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol (2012) 1.54
Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev (2012) 1.53
Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. Am J Pathol (2013) 1.53
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol (2002) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Clinical update: immunosuppression minimisation. Lancet (2007) 1.50
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2007) 1.49
Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells (2010) 1.49
L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension (2004) 1.49
Treatment of chronic proteinuric kidney disease: what next? Hypertension (2009) 1.49
Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol (2002) 1.49
Doppler ultrasonography in posttransplant renal artery stenosis: a reliable tool for assessing effectiveness of revascularization? Transplantation (2003) 1.47
Kidney regeneration. Lancet (2010) 1.47
Mechanisms and treatment of CKD. J Am Soc Nephrol (2012) 1.46
Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol (2009) 1.45
Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med (2010) 1.44
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care (2010) 1.44
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J (2011) 1.43
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrol Dial Transplant (2003) 1.43
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42